Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Reexamination Certificate
2002-07-10
2010-12-28
Skelding, Zachary (Department: 1644)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
C424S811000
Reexamination Certificate
active
07858095
ABSTRACT:
Methods and compositions for treating or preventing fibrotic disorders, e.g., sclerotic disorders, for example scleroderma, using CD2-binding agents, e.g., LFA-3/IgG fusion polypeptides or LFA-3-binding agents, are provided.
REFERENCES:
patent: 4579844 (1986-04-01), Rovee et al.
patent: 4681760 (1987-07-01), Fathman
patent: 4738297 (1988-04-01), Taniguchi et al.
patent: 4738927 (1988-04-01), Taniguchi et al.
patent: 4816397 (1989-03-01), Boss et al.
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 4833092 (1989-05-01), Geysen
patent: 4956281 (1990-09-01), Wallner et al.
patent: 5047336 (1991-09-01), Cate et al.
patent: 5116964 (1992-05-01), Capon et al.
patent: 5122514 (1992-06-01), Boger et al.
patent: 5185441 (1993-02-01), Wallner et al.
patent: 5190859 (1993-03-01), Dustin et al.
patent: 5225538 (1993-07-01), Capon et al.
patent: 5336603 (1994-08-01), Capon et al.
patent: 5547853 (1996-08-01), Wallner et al.
patent: 5556943 (1996-09-01), Yamashita et al.
patent: 5565335 (1996-10-01), Capon et al.
patent: 5728677 (1998-03-01), Wallner et al.
patent: 5730979 (1998-03-01), Bazin et al.
patent: 5817311 (1998-10-01), Bazin et al.
patent: 5914111 (1999-06-01), Wallner et al.
patent: 5928643 (1999-07-01), Wallner et al.
patent: 5951983 (1999-09-01), Bazin et al.
patent: 5952499 (1999-09-01), Whittaker et al.
patent: 6117655 (2000-09-01), Capon et al.
patent: 6162432 (2000-12-01), Wallner et al.
patent: 6270766 (2001-08-01), Feldman et al.
patent: 6337337 (2002-01-01), Buck
patent: 6384198 (2002-05-01), Diegel et al.
patent: 6764681 (2004-07-01), Wallner et al.
patent: 2002/0009446 (2002-01-01), Magilavy
patent: 2003/0044406 (2003-03-01), Dingivan
patent: 2003/0068320 (2003-04-01), Dingivan
patent: 2003/0185824 (2003-10-01), Vaishnaw et al.
patent: 2120500 (1993-04-01), None
patent: 1326940 (1994-02-01), None
patent: 1338078 (1996-02-01), None
patent: 0 200 412 (1986-12-01), None
patent: 0 260 880 (1988-03-01), None
patent: 0 280 578 (1988-08-01), None
patent: 0 314 317 (1989-03-01), None
patent: 0 325 266 (1989-07-01), None
patent: 0 345 466 (1989-12-01), None
patent: 0 368 684 (1990-05-01), None
patent: 0 503 646 (1992-09-01), None
patent: 0 503 648 (1992-09-01), None
patent: 0 517 174 (1992-12-01), None
patent: 0 325 262 (1994-03-01), None
patent: 0 626 447 (1994-11-01), None
patent: 0 607 332 (1997-12-01), None
patent: 1 637 155 (2006-03-01), None
patent: 63-233917 (1988-09-01), None
patent: 2-501113 (1990-04-01), None
patent: 1-502875 (1990-10-01), None
patent: 2-503269 (1990-10-01), None
patent: 7-502495 (1995-03-01), None
patent: WO 88/06592 (1988-09-01), None
patent: WO 88/07089 (1988-09-01), None
patent: WO 88/09820 (1988-12-01), None
patent: WO 89/02922 (1989-04-01), None
patent: WO 89/07452 (1989-08-01), None
patent: WO 90/02181 (1990-03-01), None
patent: WO 90/07517 (1990-07-01), None
patent: WO 90/08187 (1990-07-01), None
patent: WO 90/09195 (1990-08-01), None
patent: WO 90/12099 (1990-10-01), None
patent: WO 91/07987 (1991-06-01), None
patent: WO 91/10741 (1991-07-01), None
patent: WO 91/11194 (1991-08-01), None
patent: WO 91/11461 (1991-08-01), None
patent: WO 92/07581 (1992-05-01), None
patent: WO 93/06852 (1993-04-01), None
patent: WO 93/06866 (1993-04-01), None
patent: WO 95/24217 (1995-09-01), None
patent: WO 98/05357 (1998-02-01), None
patent: WO 02/060480 (2002-08-01), None
patent: WO 03/009740 (2003-02-01), None
Selman et al., Ann Intern Med. Jan. 16, 2001;134(2):136-51.
Troughton et al., Baillieres Clin Rheumatol. May 1994;8(2):439-63.
Ball et al., Angew Chem Int Ed Engl. May 3, 2005;44(19):2852-2869.
Ziwei Huang, Pharmacol Ther. Jun. 2000;86(3):201-15.
The Merriam-Webster Online, http://www.m-w.com/cgi-bin/dictionary?interstitial as accessed on Dec. 27, 2007, 1 page. Mavilia et al., Am J Pathol. Dec. 1997;151(6):1751-8.
The Merck Manual of Diagnosis and Therapy, Mark Beers and Robert Berkow, eds., Published by Merck Research Laboratories, 17th ed., 1999, pp. 431-433.
Mayes et al., Environ Health Perspect. Oct. 1999;107 Suppl 5:743-8.
Mavilia et al., Am J Pathol. Dec. 1997;151(6):1751-8.
Jefferis et al., Immunol Rev. Jun. 1998;163:59-76.
Janeway et al., Immunobiology, 3rd Ed., Garland Science, pp. 7:4-7:7, (1997).
Sato et al., Curr Opin Rheumatol. Nov. 1999;11(6):503-7.
Denton et al., Clin Exp Immunol 1998; 114:293-300.
John Varga, Curr Rheumatol Rep. Dec. 2000;2(6):481-5.
Abraham et al. (1990) “Interactions between lymphocytes and dermal fibroblasts: An in vitro model of cutaneous lymphocyte trafficking,” Experimental Cell Research 190, 118-126.
Abraham, et al., (1991) “Expression and Function of Surface Antigens on Scleroderma Fibroblasts” Arthritis and Rheumatism 34(9):1164-1172.
Actis, et al., “Continuously Infused Cyclosporine at Low Dose Is Sufficient to Avoid Emergency Colectomy in Acute Attacks of Ulcerative Colitis Without the Need for High-Dose Steroids”, Journal of Clinical Gastroenterology, vol. 17,No. 1, pp. 10-13, 1993.
Adams, “How the Immune System Works and Why it Causes Autoimmune Diseases” Immunology Today, Jul. 1996;17(7):300-2.
Albert-Wolf, et al., “Immunomodulatory Properties of Soluble Recombinant Human CD58 (LFA-3) Molecules”, Dev. Biol. Standard 77:87-92 (1992).
Alberts et al., Molecular Biology of the Cell, 1994, Garland Publishing, Inc., New York; NY, pp. 1243, 1994.
Alcover, et al., “Interdependence of CD3-Ti and CD2 Activation Pathways in Human T Lymphocytes”, The EMBO Journal, vol. 7, No. 7, pp. 1973-1977, 1988.
Alora, et al., “Narrow-band (311 nm) UVB Phototherapy: An Audit of the First Year's experience at the Massachusetts General Hospital”, Photodermatology Photoimmunology &Photomedicine,vol. 13, pp. 82-84, 1997.
Altman et al. (1990) “Transfection of genes for cell surface products involved in antigen presentation-applications to the understanding of autoimmunity” Autoimmunity 7:213-220.
Altmeyer, et al. “Traitement Systemique Du Psoriasis Par Les Derives De L'Acide Fumarique”, Ann. Dermatol. Venereol, vol. 123, pp. 838-841, 1996.
Altshuler, “Implications of Psoriasis as a New Disease”, Dermatology, vol. 199, pp. 1-2, 1999.
Ameen, “Genetic basis of psoriasis vulgaris and its pharmacogenetic potential”, Pharmacogenomics 4(3); 297-308 (2003).
Arbuckle, et al., “Psoriasis” Pediatrics in Review, Mar. 1998;19(3):106-7.
Arellano, “Risk of Cancer with Cyclosporine in Psoriasis” International Journal of Dermatology, vol. 36, No. 1, pp. 15-17, 1997.
Arend, “The Pathophysiology and Treatment of Rheumatoid Arthritis” Arthritis & Rheumatism, vol. 40, No. 4, pp. 595-597, 1997.
Armitage, “Tests for Linear Trends in Proportions and Frequencies” Biometrics, 11, 375-386, 1955.
Arthos, et al., “Identification of the Residues in Human CD4 Critical for the Binding of HIV”, Cell, 57(3):469-481 (1989).
Asadullah, et al., “IL-10 Is a Key Cytokine in Psoriasis”, Journal of Clinical Investigation, vol. 101, No. 4, pp. 783-794, 1998.
Ashcroft, et al., “Clinical Measures of Disease Severity and Outcome in Psoriasis:A Critical Appraisal of their Quality” British Journal of Dermatology, vol. 141, pp. 185-191, 1999.
ATCC Cell Lines and Hybridomas 8th Edition 1994 p. 420 only.
Baadsgaard et al. (1989) “Psoriac Epidermal Cells Demonstrate Increased Nos. and Function of Non-Langerhans Antigen-presenting Cells” J. Invest. Dermatol. 92:190-195.
Bangha et al., “Evaluation of Topical Antipsoriatic Treatment by Chromametry, Visiometry and 20-MHz Ultrasound in the Psoriasis Plaque Test”, Skin Pharmacology, vol. 9, pp. 298-306, 1996.
Bansil, et al. “Multiple Sclerosis: Immune Mechanism and Update on Current Therapies” Annals of Neurology, 37 (S1): 87-101, 1995.
Barbosa et al. (1986) “Gene Mapping and Somatic Cell Hybrid Analysis Of the Role Of Human Lymphocyte Function-Associated Antigen-3 (LFA-3) in CTL-Target Cell Interactions” J. Immunol. 136 (8)
Astellas US LLC
Leydig , Voit & Mayer, Ltd.
Skelding Zachary
LandOfFree
Method for treating or preventing sclerotic disorders using... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for treating or preventing sclerotic disorders using..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for treating or preventing sclerotic disorders using... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4209337